← Leaderboards
Mark N Feinglos
Duke University
$8,642,419
Attributed
$8,642,419
Total exposure
9
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $339.7K · FY2005–15$500K$375K$250K$125K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
Funding mix
By agency
NIH$8,642,419 · 9
By mechanism
M01$5,398,522 · 8
T32$3,243,897 · 1
Top collaborators
No co-investigators on record.
Most similar at Duke University
Same institution · by research overlap
- Marilyn J Telen$25,715,109
- Timothy J McMahon$5,782,284
- Russell E Ware$48,672,245
- Matthew J. Crowley$1,684,041
- Mark Wesley Dewhirst$12,821,035
Others in their field
Top investigators on “Clinical Research”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,040,569,537
- Leonard Freedman · Leidos Biomedical Research, Inc.$975,089,882
- Lawrence Corey · Fred Hutchinson Cancer Center$739,766,552
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Jeffrey P Krischer · University Of South Florida$611,867,176
- Barton F Haynes · Duke University$538,862,577
Research focus
Clinical ResearchHuman SubjectDiabetes Mellitus TherapyHuman Therapy EvaluationInsulinNoninsulin Dependent Diabetes MellitusDrug Screening /EvaluationInhalation Drug AdministrationDrug Adverse EffectHypoglycemic AgentsBlood GlucoseCombination ChemotherapyDrug Administration RoutesHypoglycemiaTraining ProgramsEnzyme InhibitorsEndocrinologyGlycationDiabetes MellitusInsulin Dependent Diabetes MellitusPlacebosQuality Of LifeHemoglobin AsHemoglobin
Grant awards (57)
Endocrinology and Metabolism Research Training Program$291,387
T32 · FY2015 · DK · contact PI
Endocrinology and Metabolism Research Training Program$279,683
T32 · FY2014 · DK · contact PI
Endocrinology and Diabetes Training Program$276,575
T32 · FY2012 · DK · contact PI
Endocrinology and Diabetes Training Program$267,339
T32 · FY2011 · DK · contact PI
Endocrinology and Diabetes Training Program$253,365
T32 · FY2010 · DK · contact PI
Endocrinology and Diabetes Training Program$234,848
T32 · FY2009 · DK · contact PI
Endocrinology and Diabetes Training Program$226,867
T32 · FY2008 · DK · contact PI
Endocrinology and Diabetes Training Program$68,222
T32 · FY2008 · DK · contact PI
Endocrinology and Metabolism Training Program$218,600
T32 · FY2007 · DK · contact PI
Endocrinology and Metabolism Training Program$68,869
T32 · FY2007 · DK · contact PI
Endocrinology and Metabolism Training Program$334,485
T32 · FY2006 · DK · contact PI
Endocrinology and Metabolism Training Program$271,812
T32 · FY2005 · DK
Endocrinology and Metabolism Training Program$67,883
T32 · FY2005 · DK
Endocrinology and Metabolism Training Program$132,021
T32 · FY2004 · DK
Endocrinology and Metabolism Training Program$251,941
T32 · FY2003 · DK
INHALED HUMAN INSULIN IN TYPE 2 DM ON SULFONYLUREA AND/OR METFORMIN$117,022
M01 · FY2002 · RR
VOGLIBOSE IN TYPE II DIABETES$117,022
M01 · FY2002 · RR
INHALED HUMAN INSULIN VERSUS SUBCUTANEOUS THERAPY IN TYPE I DM$117,022
M01 · FY2002 · RR
INHALED HUMAN INSULIN VERSUS USUAL SUBCUTANEOUS INSULIN$117,022
M01 · FY2002 · RR
COMBINED GLUCOTROL XL &ACARBOSE THERAPY IN TYPE II DM$117,022
M01 · FY2002 · RR
PH III: HOE901 VS NPH HUMAN INSULIN IN TYPE II DIABETES$117,022
M01 · FY2002 · RR
HOE901 VERSUS NPH HUMAN INSULIN WITH TYPE I DIABETES MELLITUS$117,022
M01 · FY2002 · RR
OPEN LABEL EXTENTION OF VOGLIBOSE IN TYPE II DIABETES MELLITUS$117,022
M01 · FY2002 · RR
HOE901 VERSUS NPH HUMAN INSULIN WITH TYPE I DIABETES MELLITUS$293,069
M01 · FY2001 · RR
COMBINED GLUCOTROL XL &ACARBOSE THERAPY IN TYPE II DM$293,069
M01 · FY2001 · RR
INHALED HUMAN INSULIN VERSUS USUAL SUBCUTANEOUS INSULIN$293,069
M01 · FY2001 · RR
INHALED HUMAN INSULIN VERSUS SUBCUTANEOUS THERAPY IN TYPE I DM$293,069
M01 · FY2001 · RR
VOGLIBOSE IN TYPE II DIABETES$293,069
M01 · FY2001 · RR
OPEN LABEL EXTENTION OF VOGLIBOSE IN TYPE II DIABETES MELLITUS$293,069
M01 · FY2001 · RR
INHALED HUMAN INSULIN IN TYPE 2 DM ON SULFONYLUREA AND/OR METFORMIN$293,069
M01 · FY2001 · RR
PH III: HOE901 VS NPH HUMAN INSULIN IN TYPE II DIABETES$293,069
M01 · FY2001 · RR
HOE901 VERSUS NPH HUMAN INSULIN WITH TYPE I DIABETES MELLITUS$117,022
M01 · FY2001 · RR
PH III: HOE901 VS NPH HUMAN INSULIN IN TYPE II DIABETES$117,022
M01 · FY2001 · RR
OPEN LABEL EXTENTION OF VOGLIBOSE IN TYPE II DIABETES MELLITUS$117,022
M01 · FY2001 · RR
VOGLIBOSE IN TYPE II DIABETES$117,022
M01 · FY2001 · RR
VOGLIBOSE IN TYPE II DIABETES$117,022
M01 · FY2001 · RR
INHALED HUMAN INSULIN VERSUS SUBCUTANEOUS THERAPY IN TYPE I DM$117,022
M01 · FY2001 · RR
INHALED HUMAN INSULIN VERSUS SUBCUTANEOUS THERAPY IN TYPE I DM$117,022
M01 · FY2001 · RR
INHALED HUMAN INSULIN VERSUS USUAL SUBCUTANEOUS INSULIN$117,022
M01 · FY2001 · RR
INHALED HUMAN INSULIN VERSUS USUAL SUBCUTANEOUS INSULIN$117,022
M01 · FY2001 · RR
COMBINED GLUCOTROL XL &ACARBOSE THERAPY IN TYPE II DM$117,022
M01 · FY2001 · RR
COMBINED GLUCOTROL XL &ACARBOSE THERAPY IN TYPE II DM$117,022
M01 · FY2001 · RR
PH III: HOE901 VS NPH HUMAN INSULIN IN TYPE II DIABETES$117,022
M01 · FY2001 · RR
HOE901 VERSUS NPH HUMAN INSULIN WITH TYPE I DIABETES MELLITUS$117,022
M01 · FY2001 · RR
INHALED HUMAN INSULIN IN TYPE 2 DM ON SULFONYLUREA AND/OR METFORMIN$117,022
M01 · FY2001 · RR
INHALED HUMAN INSULIN IN TYPE 2 DM ON SULFONYLUREA AND/OR METFORMIN$117,022
M01 · FY2001 · RR
OPEN LABEL EXTENTION OF VOGLIBOSE IN TYPE II DIABETES MELLITUS$117,022
M01 · FY2001 · RR
VOGLIBOSE IN TYPE II DIABETES$40,907
M01 · FY2000 · RR
PH III: HOE901 VS NPH HUMAN INSULIN IN TYPE II DIABETES$40,907
M01 · FY2000 · RR
HOE901 VERSUS NPH HUMAN INSULIN WITH TYPE I DIABETES MELLITUS$40,907
M01 · FY2000 · RR
INHALED HUMAN INSULIN IN TYPE 2 DM ON SULFONYLUREA AND/OR METFORMIN$40,907
M01 · FY2000 · RR
INHALED HUMAN INSULIN VERSUS SUBCUTANEOUS THERAPY IN TYPE I DM$40,907
M01 · FY2000 · RR
OPEN LABEL EXTENTION OF VOGLIBOSE IN TYPE II DIABETES MELLITUS$40,907
M01 · FY2000 · RR
INHALED HUMAN INSULIN VERSUS USUAL SUBCUTANEOUS INSULIN$0
M01 · FY2000 · RR
COMBINED GLUCOTROL XL &ACARBOSE THERAPY IN TYPE II DM$0
M01 · FY2000 · RR
COMBINED GLUCOTROL XL &ACARBOSE THERAPY IN TYPE II DM$0
M01 · FY2000 · RR
INHALED HUMAN INSULIN VERSUS USUAL SUBCUTANEOUS INSULIN$0
M01 · FY2000 · RR